Colorectal Cancer

Results from the phase 3 CheckMate-8HW trial highlight that the safety of frontline nivolumab plus ipilimumab in microsatellite instability–high or mismatch repair deficient is comparable with prior reports.

Real-world data may elucidate the characteristics and factors that influence long-term remission with regorafenib among patients with metastatic colorectal cancer.

Findings from the phase 3 FRESCO-2 trial support fruquintinib’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.

The DeFianCe trial is using DKN-01 plus bevacizumab and chemotherapy to determine if a clinical benefit would occur in patients with microsatellite stable colorectal adenocarcinoma.

Data demonstrate efficacy of robotic surgery for colectomies, which is swiftly becoming the 'preferred approach' for surgeons.

Kristen K. Ciombor, MD, MSCI, gives an overview of the current treatment landscape for patients with metastatic colorectal cancer.

The safety profile of the phase 3 RELATIVITY-123 trial is not the cause of the discontinuation, as safety is consistent with prior trials assessing the combination.

Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, conclude their discussion with advice for clinicians treating patients with metastatic colorectal cancer.

Colorectal cancer specialists discuss the effect of the SUNLIGHT trial data on the overall treatment and research landscapes.

The safety profile of nivolumab plus ipilimumab in the phase 3 CheckMate 8HW trial is comparable with prior reports of each individual agent.

Experts on colorectal cancer provide their key takeaways from the results from the SUNLIGHT study.

A comprehensive review of outcome data from the SUNLIGHT clinical trial in patients with refractory metastatic colorectal cancer.

Marwan G. Fakih, MD, reviews the study design for the SUNLIGHT clinical trial investigating trifluridine-tipiracil plus bevacizumab in patients with refractory metastatic CRC.

A brief overview of treatment options available for patients with colorectal cancer prior to the SUNLIGHT study.

Comprehensive insights on the stratification, diagnosis, and treatment of patients with metastatic colorectal cancer.

Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, introduce themselves and give an overview of metastatic colorectal cancer (mCRC).

A study conducted by the American Cancer Society found patients who were Black received worse care for colorectal cancer treatment, with health insurance is the leading cause of racial disparities.

Drs Cohen, Wu, and Ahn discuss HER2 in colorectal cancer, explaining that increased expression indicates possible benefit from HER2 inhibitors; Ahn summarized studies showing modest activity of dual HER2 inhibition compared to single agent trastuzumab.

Drs Wu, Ciombor, and Cohen discussed upfront molecular testing in patients with colorectal cancer to guide treatment, with Dr Ciombor reviewing HER2 testing methods and Dr Cohen noting liquid biopsy limitations.

Arvind N. Dasari, MD, lead investigator of the FRESCO-2 trial, spoke about the recent approval of fruquintinib for patients with previously treated metastatic colorectal cancer.

Results from the phase 3 FRESCO-2 trial support the approval of fruquintinib for patients with previously treated metastatic colorectal cancer.

CHM 2101 will be assessed as part of a phase 1A/B clinical study in a population of patients diagnosed with advanced colorectal cancer, gastric cancer, and neuroendocrine cancer.

Drs Ahn and Cohen discuss the treatment of colorectal cancer, reviewing the available options and describing factors influencing treatment choice and use of maintenance therapy after initial response.

Stacy A. Cohen, MD, provides an overview of colorectal cancer, noting increasing incidence in younger patients; Christina S. Wu, MB, BCh, MD, discussed possible reasons for more colorectal cancer in younger people, including genetic predisposition and exposures, though the causes remain unclear.

Survival following relapse appears to be shorter in patients with stage III colon cancer harboring KRAS exon 2 and BRAF V600E mutations regardless of microsatellite stability status.

Sotorasib plus panitumumab demonstrate consistent efficacy across key patient subgroups with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations in the phase 3 CodeBreaK 300 trial.

Approval of the CRCdx RAS Mutation Detection Kit may improve access to panitumumab for the treatment of patients with colorectal cancer.

Tanios S. Bekaii-Saab, MD, gave an overview of colorectal cancer along with current standard of care, and potential treatment options.

Data from the phase 2 SAMCO-PRODIGE 54 trial may support the use of immune checkpoint inhibitors over standard second-line therapy in mismatch repair–deficient and/or microsatellite instability–high metastatic colorectal cancer.

Christina Wu, MB, BCh, MD, closes the program by expressing the necessity of enrolling patients with BRAF-mutant metastatic colorectal cancer in clinical trials, highlighting a second-line study led by the Southwest Oncology Group, new BRAF inhibitors, early phase studies at the Mayo Clinic, and an exciting study in the adjuvant setting.